Merck’s acquisition strategy clearly reflects its commitment to constructing a portfolio extending beyond oncology. For instance, the recent $680 million acquisition of Harpoon Therapeutics ...

While Merck faces the inevitable Keytruda patent cliff in 2028, the company is positioning itself for continued growth through strategic diversification and pipeline expansion. Earlier this month ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other products. Read why MRK is a Buy.

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial. The study tested a ...

In the latest trading session, Merck (MRK) closed at $78.83, marking a -1.05% move from the previous day. This change lagged the S&P 500's 0.8% gain on the day. Meanwhile, the Dow gained 0.94% ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages ...

Merck will continue to step up for patients, taking a more impact-orientated approach to work with them, their carers and patient advocacy groups.

This story is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 ...

Review the current Merck & Co Inc (MRK:XNYS) dividend yield and history to decide if MRK is the best investment for you.

Review Merck & Co Inc (MRK:XNYS) stock and the current sustainability and ESG risk rating to help with your investing decisions.

Merck & Co Share Price Live Today:Get the Live stock price of MRK Inc., and quote, performance, latest news to help you with stock trading and investing.Check out why Merck & Co share price is up ...